Medtech sector bullish about 2010 despite economic and regulatory challenges
This article was originally published in Clinica
Despite the current economic climate and the increasing regulatory burden, a survey of over 1,000 medtech professionals shows that, globally, the sector’s outlook remains “very optimistic”.
You may also be interested in...
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.
Suppliers to the UK’s National Health Service from outside the EU could save up to 12% in costs for some equipment during COVID-19 emergency measures as the UK tries to increase supplies